LCTX EBITDA | Lineage Cell Therapeutics, Inc.

Lineage Cell Therapeutics, Inc. (LCTX) EBITDA

2026-06-30: Basis Reported; EBITDA (m); Operating income -$8.92M; Depreciation and amortization (m).
2026-03-31: Basis Reported; EBITDA (m); Operating income -$7.59M; Depreciation and amortization (m).
2025-09-30: Basis Reported; EBITDA (m); Operating income -$3.79M; Depreciation and amortization (m).
2025-06-30: Basis Reported; EBITDA (m); Operating income -$19.78M; Depreciation and amortization (m).

Complete source-backed ebitda history.

Available history: 2014-12-31 to 2023-03-31
Data captured: 2026-09-04

Historical EBITDA

EBITDA 3 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2026-06-30	Reported	(m)	-$8.92M	(m)	$1.07M	(m)	$108.00K*	-$7.24M*	(m)	$4.77M	(m)	(m)
2026-03-31	Reported	(m)	-$7.59M	(m)	$1.73M	(m)	$55.00K	-$8.08M	(m)	$4.23M	(m)	(m)
2025-09-30	Reported	(m)	-$3.79M	(m)	$3.68M	(m)	$12.00K*	-$3.62M*	(m)	$3.27M	(m)	(m)
2025-06-30	Reported	(m)	-$19.78M	(m)	$2.77M	(m)	$14.00K*	-$5.54M*	(m)	$3.11M	(m)	(m)
2025-03-31	Reported	(m)	-$6.50M	(m)	$1.50M	(m)	$97.00K	-$4.89M	(m)	$3.11M	(m)	(m)
2024-09-30	Reported	(m)	-$3.84M	(m)	$3.78M	(m)	$112.00K*	-$5.79M*	(m)	$3.17M	(m)	$0.00
2024-06-30	Reported	(m)	-$5.87M	(m)	$1.41M	(m)	$50.00K*	-$5.18M*	(m)	$2.87M	(m)	$0.00
2024-03-31	Reported	(m)	-$6.66M	(m)	$1.44M	(m)	$38.00K	-$5.78M	(m)	$3.01M	(m)	$0.00
2023-12-31	Reported	(m)	-$6.36M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Reported	-$6.56M*	-$6.71M	$143.00K*	$1.25M	-526.65%*	$139.00K*	-$5.04M*	(m)	$3.74M	(m)	$0.00
2023-06-30	Reported	-$4.89M*	-$5.02M	$138.00K*	$3.23M	-151.50%*	$256.00K*	-$6.27M*	(m)	$3.87M	(m)	$0.00
2023-03-31	Reported	-$6.5M	(m)	(m)	(m)	-272.59%	$188.00K	-$11.24M	(m)	$4.18M	(m)	-$1.80M
2022-12-31	Reported	-$6.5M	(m)	(m)	(m)	-339.32%	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Reported	-$5.11M*	-$5.25M	$145.00K*	$3.00M	-170.31%*	$286.00K*	-$5.48M*	(m)	$3.59M	(m)	$541.00K
2022-06-30	Reported	-$4.09M*	-$4.23M	$146.00K*	(m)	(m)	$97.00K*	-$7.06M*	(m)	$3.30M	(m)	(m)
2022-03-31	Reported	-$6.25M	(m)	(m)	(m)	-128.39%	$46.00K	$21.90M	(m)	$2.99M	(m)	(m)
2021-12-31	Reported	-$28.08M	(m)	(m)	(m)	-732.18%	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Reported	-$6.68M*	-$6.84M	$166.00K*	(m)	(m)	$54.00K*	-$4.85M*	(m)	$2.81M	(m)	-$1.01M
2021-06-30	Reported	-$6.92M*	-$7.08M	$164.00K*	(m)	(m)	$129.00K*	-$5.42M*	(m)	$2.93M	(m)	(m)
2021-03-31	Reported	-$6.88M	(m)	(m)	(m)	-1758.57%	$11.00K	-$7.42M	(m)	$3.39M	(m)	(m)
2020-12-31	Reported	-$5.68M	(m)	(m)	(m)	-1600.56%	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Reported	-$6.53M	(m)	(m)	(m)	-1142.73%	$24.00K*	-$4.85M*	(m)	$3.57M	(m)	(m)
2020-06-30	Reported	-$6.19M	(m)	(m)	(m)	-1604.15%	$6.00K*	-$4.24M*	(m)	$2.81M	(m)	(m)
2020-03-31	Reported	-$7.23M	(m)	(m)	(m)	-1405.84%	$10.00K	-$5.03M	(m)	$3.34M	(m)	(m)
2019-12-31	Reported	-$6.64M	(m)	(m)	(m)	-534.73%	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Reported	-$8.17M	(m)	(m)	(m)	-1440.74%	$69.00K*	-$7.44M*	(m)	$4.27M	(m)	$1.00M
2019-06-30	Reported	-$10.58M	(m)	(m)	(m)	-1357.77%	$195.00K*	-$9.67M*	(m)	$5.24M	(m)	$1.22M*
2019-03-31	Reported	-$12.49M	(m)	(m)	(m)	-1346.12%	$169.00K	-$9.31M	(m)	$4.96M	(m)	$4.38M
2018-12-31	Reported	-$9.95M	(m)	(m)	(m)	-1312.40%	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Reported	-$10.1M	(m)	(m)	(m)	-1028.82%	$162.00K*	-$7.33M*	(m)	$4.88M	(m)	(m)
2018-06-30	Reported	-$8.87M	(m)	(m)	(m)	-348.06%	$39.00K*	-$7.40M*	(m)	$6.36M	(m)	(m)
2018-03-31	Reported	-$11.91M	(m)	(m)	(m)	-1698.43%	$198.00K	-$10.34M	(m)	$5.93M	(m)	(m)
2017-12-31	Reported	-$9.29M	(m)	(m)	(m)	-929.53%	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Reported	-$9.26M	(m)	(m)	(m)	-548.82%	$456.00K*	-$7.68M*	(m)	$6.56M	(m)	$0.00
2017-06-30	Reported	-$8.36M	(m)	(m)	(m)	-2193.96%	$259.00K*	-$9.06M*	(m)	$6.27M	(m)	(m)
2017-03-31	Reported	-$11.05M	(m)	(m)	(m)	-2832.31%	$215.00K	-$8.10M	(m)	$6.49M	(m)	(m)
2016-12-31	Reported	-$11.07M	(m)	(m)	(m)	-1022.07%	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Reported	-$9.31M*	-$9.55M	$248.00K*	(m)	(m)	(m)	-$8.91M*	(m)	$6.42M	(m)	(m)
2016-06-30	Reported	-$14.08M*	-$14.40M	$319.00K*	(m)	(m)	(m)	(m)	(m)	$8.94M	(m)	(m)
2016-03-31	Reported	-$23.33M	(m)	(m)	(m)	-1125.37%	$583.00K	(m)	(m)	$13.73M	(m)	(m)
2015-12-31	Reported	(m)	-$21.71M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Reported	(m)	-$17.10M	(m)	(m)	(m)	$209.00K*	(m)	(m)	$11.43M	(m)	(m)
2015-06-30	Reported	(m)	-$13.50M	(m)	(m)	(m)	$228.00K*	(m)	(m)	$9.06M	(m)	(m)
2015-03-31	Reported	(m)	-$13.50M	(m)	(m)	(m)	$77.00K	(m)	(m)	$9.32M	(m)	(m)
2014-12-31	Reported	(m)	-$14.40M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-09-30	Reported	(m)	-$12.14M	(m)	(m)	(m)	$92.00K*	(m)	(m)	$8.84M	(m)	-$2.31M
2014-06-30	Reported	(m)	-$13.06M	(m)	(m)	(m)	$173.08K*	(m)	(m)	$9.08M	(m)	-$1.51M
2014-03-31	Reported	(m)	-$11.14M	(m)	(m)	(m)	$231.92K	-$10.36M	(m)	$8.41M	(m)	-$1.35M
2013-12-31	Reported	(m)	-$29.29M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-09-30	Reported	(m)	-$10.20M	(m)	(m)	(m)	$1.24M*	-$6.42M*	(m)	$6.44M	(m)	$0.00
2013-06-30	Reported	(m)	-$8.12M	(m)	(m)	(m)	$239.00K*	-$7.44M*	(m)	$5.53M	(m)	$0.00
2013-03-31	Reported	(m)	-$8.38M	(m)	(m)	(m)	$496.13K	-$7.02M	(m)	$5.40M	(m)	$0.00
2012-12-31	Reported	(m)	-$7.06M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Reported	(m)	-$5.95M	(m)	(m)	(m)	$51.65K*	-$5.01M*	(m)	$4.55M	(m)	(m)
2012-06-30	Reported	(m)	-$6.08M	(m)	(m)	(m)	$36.89K*	-$3.96M*	(m)	$4.62M	(m)	(m)
2012-03-31	Reported	(m)	-$5.92M	(m)	(m)	(m)	$116.60K	-$5.72M	(m)	$4.18M	(m)	(m)
2011-12-31	Reported	(m)	-$5.45M	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2011-09-30	Reported	(m)	-$4.23M	(m)	(m)	(m)	$242.56K*	-$3.60M*	(m)	$3.49M	(m)	(m)
2011-06-30	Reported	(m)	-$4.98M	(m)	(m)	(m)	$242.17K*	-$2.80M*	(m)	$3.33M	(m)	(m)
2011-03-31	Reported	(m)	-$4.03M	(m)	(m)	(m)	$295.79K	-$3.36M	(m)	$2.95M	(m)	(m)
2010-09-30	Reported	(m)	-$2.46M	(m)	(m)	(m)	$21.67K*	-$1.99M*	(m)	-$1.81M	(m)	(m)
2010-06-30	Reported	(m)	-$2.32M	(m)	(m)	(m)	(m)	(m)	(m)	-$1.43M	(m)	(m)

EBITDA 12 month

Date	Basis	EBITDA	Operating income	Depreciation and amortization	Revenue	EBITDA margin	Capital spending	Operating cash flow	Cost of products and services	Research and development	Selling, general and administration	Income tax expense / benefit
2025-12-31	Reported	(m)	-$36.62M	(m)	$14.56M	(m)	$522.00K	-$18.92M	(m)	$17.73M	(m)	-$5.28M
2024-12-31	Reported	(m)	-$21.48M	(m)	$9.50M	(m)	$565.00K	-$23.09M	(m)	$12.47M	(m)	$0.00
2024-09-30	Rolling	(m)	-$22.73M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-06-30	Rolling	(m)	-$25.59M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2024-03-31	Rolling	(m)	-$24.75M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-12-31	Reported	(m)	-$24.73M	(m)	$8.95M	(m)	$674.00K	-$28.57M	(m)	$15.71M	(m)	-$1.80M
2023-12-31	Rolling	(m)	-$24.73M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-09-30	Rolling	(m)	-$25.01M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-06-30	Rolling	(m)	-$23.56M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2023-03-31	Rolling	(m)	-$22.77M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-12-31	Reported	-$21.94M	(m)	(m)	(m)	-149.21%	$413.00K	$1.06M	(m)	$13.99M	(m)	$541.00K
2022-12-31	Rolling	(m)	-$22.52M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-09-30	Rolling	(m)	-$44.12M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-06-30	Rolling	(m)	-$45.71M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2022-03-31	Rolling	(m)	-$48.56M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-12-31	Reported	-$48.55M	(m)	(m)	(m)	-1118.36%	$340.00K	-$23.56M	(m)	$33.91M	(m)	(m)
2021-12-31	Rolling	(m)	-$49.21M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-09-30	Rolling	(m)	-$26.86M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-06-30	Rolling	(m)	-$26.74M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2021-03-31	Rolling	(m)	-$26.06M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-12-31	Reported	-$25.62M	(m)	(m)	(m)	-1403.29%	$64.00K	-$19.75M	(m)	$12.32M	(m)	-$1.24M
2020-12-31	Rolling	(m)	-$26.45M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-09-30	Rolling	(m)	-$27.44M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-06-30	Rolling	(m)	-$29.13M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2020-03-31	Rolling	(m)	-$33.55M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-12-31	Reported	-$37.87M	(m)	(m)	(m)	-1077.50%	$440.00K	-$31.95M	(m)	$17.95M	(m)	-$7.41M
2019-12-31	Rolling	(m)	-$38.88M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-09-30	Rolling	(m)	-$42.11M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-06-30	Rolling	(m)	-$44.05M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2019-03-31	Rolling	(m)	-$42.37M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-12-31	Reported	-$40.71M	(m)	(m)	(m)	-816.24%	$556.00K	-$30.88M	(m)	$20.95M	(m)	$346.00K
2018-12-31	Rolling	(m)	-$41.80M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-09-30	Rolling	(m)	-$41.25M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-06-30	Rolling	(m)	-$40.41M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2018-03-31	Rolling	(m)	-$39.83M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-12-31	Reported	-$37.96M	(m)	(m)	(m)	-1097.60%	$1.33M	-$30.52M	(m)	$24.02M	(m)	(m)
2017-12-31	Rolling	(m)	-$38.90M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-09-30	Rolling	(m)	-$40.59M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-06-30	Rolling	(m)	-$40.63M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2017-03-31	Rolling	(m)	-$46.47M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-12-31	Reported	-$57.79M	(m)	(m)	(m)	-975.64%	$2.25M	-$42.33M	(m)	$36.11M	(m)	(m)
2016-12-31	Rolling	(m)	-$58.97M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-09-30	Rolling	(m)	-$69.42M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-06-30	Rolling	(m)	-$76.97M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2016-03-31	Rolling	(m)	-$76.06M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-12-31	Reported	-$64.73M	(m)	(m)	(m)	-920.00%	$1.24M	-$44.54M	(m)	$42.60M	(m)	(m)
2015-12-31	Rolling	(m)	-$65.81M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2015-09-30	Rolling	(m)	-$58.51M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2014-12-31	Reported	-$49.63M	(m)	(m)	(m)	-946.43%	$483.00K	(m)	(m)	$37.53M	(m)	(m)
2014-09-30	Rolling	(m)	-$65.63M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-12-31	Reported	(m)	-$55.99M	(m)	(m)	(m)	$2.28M	-$29.51M	(m)	$26.61M	(m)	(m)
2013-09-30	Rolling	(m)	-$33.76M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-06-30	Rolling	(m)	-$29.50M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2013-03-31	Rolling	(m)	-$27.47M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-12-31	Reported	(m)	-$25.00M	(m)	(m)	(m)	$400.81K	-$19.68M	(m)	$18.12M	(m)	(m)
2012-12-31	Rolling	(m)	-$25.00M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-09-30	Rolling	(m)	-$23.39M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-06-30	Rolling	(m)	-$21.67M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2012-03-31	Rolling	(m)	-$20.58M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2011-12-31	Reported	(m)	-$18.69M	(m)	(m)	(m)	$960.28K	-$13.59M	(m)	$13.70M	(m)	(m)
2011-12-31	Rolling	(m)	-$18.69M*	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)	(m)
2010-12-31	Reported	(m)	-$9.85M	(m)	(m)	(m)	$220.77K	-$7.73M	(m)	$8.19M	(m)	(m)
2009-12-31	Reported	(m)	-$3.52M	(m)	(m)	(m)	$61.28K	-$4.26M	(m)	-$3.18M	(m)	(m)

Similar stocks

Stock Name	Country	Market Cap	PE Ratio
Aligos Therapeutics, Inc. (ALGS)	United States	$0.238B	-0.47
SUTRO BIOPHARMA, INC. (STRO)	United States	$0.260B	-3.05
Protalix BioTherapeutics, Inc. (PLX)		$0.221B	9.87
ANAVEX LIFE SCIENCES CORP. (AVXL)	United States	$0.218B	-18.37
Alector, Inc. (ALEC)	United States	$0.213B	-1.90
Invivyd, Inc. (IVVD)	United States	$0.270B	-2.42
PALISADE BIO, INC. (PALI)	United States	$0.275B	-11.41
Compass Therapeutics, Inc. (CMPX)	United States	$0.204B	-5.35
Lexeo Therapeutics, Inc. (LXEO)	United States	$0.278B	-4.19
FATE THERAPEUTICS INC (FATE)	United States	$0.280B	-2.51